CAS 878672-00-5

Lesinurad

Description:

Lesinurad is a pharmaceutical compound primarily used in the treatment of gout, specifically to manage hyperuricemia associated with this condition. It functions as a selective uric acid reabsorption inhibitor, targeting the URAT1 transporter in the kidneys, which helps to increase uric acid excretion and lower serum uric acid levels. Lesinurad is typically administered in conjunction with a xanthine oxidase inhibitor, such as allopurinol, to enhance its efficacy. The compound is characterized by its relatively low solubility in water, which can influence its absorption and bioavailability. Lesinurad has been shown to effectively reduce the frequency of gout flares and improve overall patient outcomes. As with any medication, it may have side effects, including potential renal complications, and its use should be monitored by healthcare professionals. Overall, Lesinurad represents a significant advancement in the pharmacological management of gout, particularly for patients who do not achieve adequate control with traditional therapies alone.

Formula: C₁₇H₁₄BrN₃O₂S

InChI: InChI=1S/C17H14BrN3O2S/c18-16-19-20-17(24-9-15(22)23)21(16)14-8-7-11(10-5-6-10)12-3-1-2-4-13(12)14/h1-4,7-8,10H,5-6,9H2,(H,22,23)

InChI key: InChIKey=FGQFOYHRJSUHMR-UHFFFAOYSA-N

SMILES: S(CC(O)=O)C=1N(C=2C3=C(C(=CC2)C4CC4)C=CC=C3)C(Br)=NN1

Synonyms:

• 2-((5-Bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl)thio)acetic acid
• 2-[[5-Bromo-4-(4-cyclopropyl-1-naphthalenyl)-4H-1,2,4-triazol-3-yl]thio]acetic acid
• 2-[[5-Bromo-4-(4-cyclopropylnaphthalen-1-yl)-1,2,4-triazol-3-yl]sulfanyl]acetic acid
• Acetic acid, 2-[[5-bromo-4-(4-cyclopropyl-1-naphthalenyl)-4H-1,2,4-triazol-3-yl]thio]-
• Acetic acid, [[5-bromo-4-(4-cyclopropyl-1-naphthalenyl)-4H-1,2,4-triazol-3-yl]thio]-
• Lesinida
• Rdea 594
• Read 594
• Zurampic
• Lesinurad
• Lesinurad（RDEA5)
• ethyl 3-(N-(5-chloro-2-nitrophenyl)anilino)-3-oxopropanoate
• Lesinurad impurity1-12
• Recinard
• 2-{[5-broMo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}acetic acid
• Lessinurad
• Lesinuras
• Lacy Noulard
• RDEA594(Lesinurad )
• RDEA 594; RDEA-594; RDEA594
• Lesurinad
• RDEA 594 USP/EP/BP
• Lesinurad (with 3 ints.)
• Lesinurad (RDEA-594)

RDEA 594

CAS: 878672-00-5

Formula: C₁₇H₁₄BrN₃O₂S

Purity: 98%

Color and Shape: Solid

Molecular weight: 404.2810

Ref: IN-DA00GRAZ

Lesinurad

CAS: 878672-00-5

Lesinurad

Purity: ≥98%

Molecular weight: 404.28g/mol

Ref: 54-BUP15694

Lesinurad

CAS: 878672-00-5

Formula: C₁₇H₁₄BrN₃O₂S

Color and Shape: White To Off-White Solid

Molecular weight: 404.28

Ref: 4Z-L-109001

Lesinurad

CAS: 878672-00-5

Lesinurad

Purity: 98%

Molecular weight: 404.28g/mol

Ref: 54-OR1026597

Lesinurad

CAS: 878672-00-5

Lesinurad (RDEA594), a selective uric acid reabsorption inhibitor, is used to treat gout without causing liver damage.

Formula: C₁₇H₁₄BrN₃O₂S

Purity: 99.83% - 99.86%

Color and Shape: Solid

Molecular weight: 404.28

Ref: TM-T6875

Lesinurad

Controlled Product

CAS: 878672-00-5

Applications Lesinurad is used to synthesize febuxostat which is a non-purine analog inhibitor of xanthine oxidase. Febuxostat is approved by the European Medicines Agency and the US Food and Drug Administration for treating gout.
References Burns, C., et al.: Lancet 377, 165 (2011); Miner, J. et al.: PCT Int. Appl. WO 2011159732 A1 20111222 (2011); Crittenden, D. B. et al.: Clinical Investigation 1, 1563-1575 (2011)

Formula: C₁₇H₁₄BrN₃O₂S

Color and Shape: Neat

Molecular weight: 404.28

Ref: TR-L329700

Lesurinad

CAS: 878672-00-5

Inhibits urate anion exchanger 1 (URAT1); therapeutic use in gout

Formula: C₁₇H₁₄BrN₃O₂S

Purity: Min. 95%

Color and Shape: Off-White To Light (Or Pale) Yellow To Light Brown Solid

Molecular weight: 404.28 g/mol

Ref: 3D-FL65059

Lesinurad-13CD2

Controlled Product

CAS: 878672-00-5

Formula: CC₁₆D₂H₁₂BrN₃O₂S

Color and Shape: Neat

Molecular weight: 407.286

Ref: TR-L329702